Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 118,956

Document Document Title
WO/2016/129583A1
The invention provides a lactate dehydrogenase inhibitor that makes it possible to suppress refractory epilepsy in which conventional antiepileptic drugs are ineffective, and an antiepileptic drug containing said inhibitor. The lactate d...  
WO/2016/127221A1
The present invention relates to compositions, methods and kits for the treatment of pain. In particular, the compositions, methods and kits are for the treatment of pain associated with headache or migraine or period pain. In particular...  
WO/2016/130501A1
The present invention provides aza-heteroaryl derivatives of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A, W, R4, R5, and R6 are defined herein, that inhibit the activity of phosphoinositide 3-kinases-gamm...  
WO/2016/130460A9
Compounds, compositions, kits and methods for treating conditions related to Retinal degenerations, and related diseases, including retinitis pigmentosa and atrophic age-related macular degeneration, are disclosed.  
WO/2016/129140A1
An intraoral rapid disintegration tablet that comprises fine grains, said fine grains having, at the center, a drug substance-containing core containing butylscopolamine bromide and water-insoluble particles and being provided with an in...  
WO/2016/130790A1
Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Ring B, A1, A2, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for...  
WO/2016/130920A3
Compounds having the formula (I), (II), (III) are provided. Compounds of the present disclosure are useful for the treatment of neurodegenerative diseases, such as Parkinson's Disease.  
WO/2016/127832A1
The present invention provides an application of chlorogenic acid in preparing medicines for treating epilepsy. The chlorogenic acid helps to relieve an epileptic attack.  
WO/2016/124788A1
The invention relates to a system for the intranasal sequential administration of at least one active principle pertaining to the group of active principles having at least one respiratory depression RD side effect and at least one activ...  
WO/2016/127068A1
Methods of treating postherpetic neuralgia in a mammal with a pharmaceutical composition comprising a spiro-oxindole compound of the formula:(the formula should be inserted here), are disclosed. The methods provide excellent penetration ...  
WO/2016/124129A1
Disclosed are a series of diaza-benzofluoranthrene compounds. The present invention particularly relates to a compound represented by formula (I), pharmaceutically acceptable salts or tautomers thereof.  
WO/2016/126572A2
Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthas...  
WO/2016/124642A1
The invention relates to the field of medicine and nutrition, more specifically to the field of treatment and prevention of human disorders such as depression, rumination, aggression, migraine, autistic spectrum disorders (including auti...  
WO/2016/126995A1
The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disord...  
WO/2016/125187A4
The patent discloses novel quinoline derivatives of formula (I), (Formula should be inserted here) and process for preparing the same. The compounds of formula (I) can be further used for the synthesis of Inhibitors like Kinase Tyrosine ...  
WO/2016/126929A1
The disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and dis...  
WO/2016/125190A3
Crystalline forms of vortioxetine hydrobromide, designated as form-M1, form-M2, form-M3, and form-M4are disclosed herein.The present disclosure also provides apharmaceutical premix of crystalline form-M2 of vortioxetine hydrobromide and ...  
WO/2016/126169A1
The invention is based on the use of acetyl-L-carnitine (ALC) as a means for increasing the effectiveness of antidepressive treatment and can be used in a clinic in antidepressive treatment with non-natural antidepressants, such as ag...  
WO/2016/125190A2
Crystalline forms of vortioxetine hydrobromide, designated as form-M1, form-M2, form-M3, and form-M4are disclosed herein.The present disclosure also provides apharmaceutical premix of crystalline form-M2 of vortioxetine hydrobromide and ...  
WO/2016/125187A1
The patent discloses novel quinoline derivatives of formula (I), (Formula should be inserted here) and process for preparing the same. The compounds of formula (I) can be further used for the synthesis of Inhibitors like Kinase Tyrosine ...  
WO/2016/125208A1
The object of the invention is to provide a functional unknown material in which a natural product is used as a raw material. One embodiment of the invention is a yeast fermentation product of the nest of birds belonging to the genus Col...  
WO/2016/124508A1
The invention relates to 9H-pyrrolo-dipyridine derivatives of formula I, processes for preparing them, pharmaceutical compositions containing them and their use as radiopharmaceuticals in particular as imaging agents for the detection of...  
WO/2016/127135A1
Disclosed herein are compounds that are effective for treatment of various disease states. Dosing includes both single administration and regimens of cycling dosages.  
WO/2016/124976A1
The invention relates to short RVG derived peptides for use in delivering therapeutic agents across the blood brain barrier and to target cells, for example those cells in the central nervous system. The invention provides method and com...  
WO/2016/124140A1
Disclosed are heterocyclic-substituted N-sulfonylbenzamide derivatives, a preparation method for the derivatives, and a pharmaceutical use of the derivatives. Specifically, disclosed are compounds of formula (II) or pharmaceutically acce...  
WO/2016/126926A1
The present disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections...  
WO/2016/127170A1
The disclosure provides an injectable ganaxolone formulation comprising ganaxolone, sulfobutyl ether-β-cyclodextrin; and water. The injectable ganaxolone formulation optionally includes a surfactant and a pH modifier. The ganaxolone and...  
WO/2016/124564A1
The invention relates to n-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyrazi n-3-carboxamide derivatives as stimulators of soluble guanylate cyclase (sGC) for the treatment of cardiovascular diseases, such as for e...  
WO/2016/124125A1
The present invention relates to a new crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxa mide hydrochloride and a preparation method for the new crystalline form. The crystalline form has advantageous prope...  
WO/2016/124141A1
Disclosed are heterocyclic-substituted N-sulfonylbenzamide derivatives, a preparation method for the derivatives, and a pharmaceutical use of the derivatives. Specifically, disclosed are compounds of formula (II) or pharmaceutically acce...  
WO/2016/126572A3
Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthas...  
WO/2016/127085A1
Novel diphenylurea and benzylbenzenesulfonamide compounds are disclosed along with methods of inhibiting the activity of TRPV1 and methods of treating pain associated with transient receptor potential vanilloid type 1 (TRPV1) using such ...  
WO/2016/124960A1
The present invention provides pharmaceutical compositions comprising compounds of Formula (I), and methods of treating neurological disorders comprising administering to a subject in need thereof a pharmaceutical composition comprising ...  
WO/2016/123581A1
The present invention provides a malonate salt of a compound of formula (I), which is a crystalline salt. Also provided are pharmaceutical compositions that include the provided malonate salt and methods of using the provided crystalline...  
WO/2016/123627A1
Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); pharmaceutical compositions comprising the compounds; and methods of using the compounds, for...  
WO/2016/123577A1
The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula (I), or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, in...  
WO/2016/123164A1
Disclosed are 2-phenyl-cyclopropylmethanamines which are selective 5-HT(2C) receptor agonists and are used in the treatments of diseases and conditions wherein modulation of 5-HT(2C) receptors provides a benefit, such as obesity and psyc...  
WO/2016/122218A3
The present invention relates to a composition and method for combinative therapy, capable of temporarily regulating inherent dysfunctional neural processes and reducing symptoms and/or signs of neuropsychiatric disorders including, but ...  
WO/2016/122832A1
Disclosed are compositions comprising Rg3 ginsenoside and nicotinamide riboside. These compositions are useful for treating and preventing diseases, conditions and disorders caused by microglia-mediated inflammation, including neurodegen...  
WO/2016/122968A1
The present invention provides a tosylate salt of N-[3-[(4aR,7aS)-2-amino-6-(5- fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3] thiazin-7a-yl]-4-fluoro- phenyl]-5-methoxy-pyrazine-2-carboxamide.  
WO/2016/119701A1
The present invention relates to a novel type of PPARγ modulator having a pyrimido [5, 4-d]pyrimidine main structure. The PPARγ modulator can enhance the expression and nuclear translocation of PPARγ in cells. The present invention al...  
WO/2016/119031A8
The present invention describes a new compound, the method for synthetising same and the use of this compound, as well as a pharmaceutical composition containing said compound. Specifically, the present invention discloses a compound of ...  
WO/2016/119700A1
Provided herein are substituted imidazo [1, 2-a] pyridin-2-ylamine compounds, for example, of formula (A), and pharmaceutical compositions thereof; and methods of their use for treating, preventing, or ameliorating one or more symptoms o...  
WO/2016/119031A1
The present invention describes a new compound, the method for synthetising same and the use of this compound, as well as a pharmaceutical composition containing said compound. Specifically, the present invention discloses a compound of ...  
WO/2016/123533A1
Substituted 1,2,3-triazole compounds are disclosed which have utility in the treatment of a variety of neurological disorders. The compounds provided herein have the general structure wherein R1, R2, R3 and n are as defined herein, inclu...  
WO/2016/123543A1
Disclosed herein are methods for treating schizophrenia in an individual. The invention further provides methods for determining if an individual suffering from schizophrenia is likely to respond favorably or experience an enhanced treat...  
WO/2016/121805A1
Provided is an adhesive patch capable of exhibiting exceptional tack on the skin when affixed thereto, said patch having a low incidence of detaching from the skin once affixed. This adhesive patch is characterized by including a support...  
WO/2016/122218A2
The present invention relates to a composition and method for combinative therapy, capable of temporarily regulating inherent dysfunctional neural processes and reducing symptoms and/or signs of neuropsychiatric disorders including, but ...  
WO/2016/119085A1
Disclosed is an application of ethyl p-methoxycinnamate and derivatives thereof in preparing drugs, culture media, regulating agents or cosmetics and skin care products for maintaining self-renewal and pluripotency of stem cells. The ste...  
WO/2016/118541A1
Provided herein are ergoline compounds and pharmaceutical compositions thereof. In some embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine u...  

Matches 351 - 400 out of 118,956